

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/506,748	Applicant: Birch <i>et al</i>
371 Filing Date: 09/03/2004	Attorney Docket No.: 100662-1P US
Examiner: Seaman, D Margaret M	Group Art Unit: 1625
Customer No.: 44992	Confirmation No.: 6588
Title: Indole-Amide Derivatives And Their Use As Glycogen Phosphorylase Inhibitors	

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Second Supplemental Information Disclosure Statement**

Sir:

Applicants are submitting a third information disclosure statement. This statement lists 9 new references and 4 references which were disclosed previously. These 4 references are being resubmitted because although the correct documents were sent in March 2005 and appear on PAIR, there were typographical errors in the corresponding bibliographic details on the SB08. Applicants wish the correct bibliographic details to appear on the front page of any patent resulting from this application.

Specifically the following errors have been corrected:

- 2) JP 2001247565 was incorrectly listed as JP021247565. The Applicant should have been listed as Pfizer Prod Inc. The correct publication date is 11<sup>th</sup> September 2001. Applicants are submitting both the JP application and an English abstract at this time.
- 3) J Het Chem, (1974), 11(2), 143-150 - the journal title was missing from the SB08.
- 4) Teague et al, Diabetes, Vol 52 supp 2, A365, 1521-P - on the SB08 Vol 53 was listed instead of 52 and suppl 1 instead of 2.
- 5) Vertigan et al, Diabetologia, vol 47, supp 1, A214, 589 - The journal was listed as Diabetes instead of Diabetologia.

The Examiner is respectfully requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed SB08.

Respectfully submitted,

/Lucy Padget/

Name: Lucy Padget  
Dated: April 7<sup>th</sup>, 2006  
Reg. No.: L0074  
Phone No.: 781-839-4182  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 02451